<DOC>
	<DOC>NCT00861614</DOC>
	<brief_summary>The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone</brief_summary>
	<brief_title>Study of Immunotherapy to Treat Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Advanced prostate cancer At least 1 bone metastasis Testosterone &lt; 50 ng/dl Prior treatment with docetaxel Brain metastasis Autoimmune disease Known HIV, Hep B, or Hep C infection More than 2 prior systemic anticancer regimens for prostate cancer Prior treatment on BMS CA180227 for prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>